

## Strengthening the Nation's Capacity to Respond to Domestic Infectious Diseases

CDC's *Epidemiology and Laboratory Capacity for Prevention and Control of Emerging Infectious Diseases Cooperative Agreement* (ELC) provides financial support and technical assistance to the nation's health departments to **detect, prevent, and respond to emerging infectious diseases**. ELC's **64 recipients**, which consist of state, large local, and U.S. territory and affiliate health departments, serve as the foundation for our national public health infrastructure and are integral to the nation's ability to tackle infectious disease threats.

The ELC accomplishes its mission through a unique structure of four robust public health programs; cross-cutting projects focusing on leadership, integration, flexibility, and sustainability; and a range of disease-specific projects. ELC also distributes supplemental funding on behalf of CDC for emergency response efforts, such as those for the influenza H1N1, Zika, and Ebola epidemics, and most recently, the COVID-19 pandemic.

### Our Structure: What Sets ELC Apart




Flexible funding provides recipients **the ability to meet their own changing needs**, instead of a one-size-fits-all strategy.



Disease-specific projects allow for **prioritization of health topics** specific to certain areas or populations, such as Legionnaire's disease or vaccine-preventable diseases.



Funding for leadership and management supports **strategic planning and management** of ELC resources.



Cross-cutting projects and programs **enhance collaboration** between state epidemiology and laboratory, as well as local public health departments.

**In 2022**, ELC awarded approximately **\$197M** to its **64 recipients** in core funding to continue the crucial work of health departments across the United States.

Learn more about ELC at: [www.cdc.gov/elc](http://www.cdc.gov/elc)

## 2022-2023: Budget Period 4 Core Funding

Programs	Recipients	Award Amount
Cross-Cutting: Epidemiology & Laboratory Capacity	61	\$22,380,473
Foodborne, Waterborne, Enteric, & Environmentally Transmitted Diseases Program	59	\$33,833,495
Healthcare-associated Infections & Antibiotic Resistance Program	56	\$56,380,238
Vector-Borne Diseases Program	62	\$16,231,028

Cross-Cutting Projects	Recipients	Award Amount
ELC Leadership, Management & Administration	63	\$5,478,557
Health Information Systems Capacity	63	\$21,338,177
Data Modernization	0	\$0*
Impact & Evaluation	4	\$510,180
Cross-Cutting Emerging Issues Project: Enhanced Surveillance, Outbreak Investigation Response & Reporting, Surge Efforts & Interventions	64	<i>Available for emerging issues</i>

Disease- Specific Projects	Recipients	Award Amount
Mycotics: Detecting & Preventing Fungal Infections	30	\$1,024,975
Binational Border Infectious Disease Surveillance (BIDS) Program	4	\$1,814,032
Global Migration, Border Interventions, and Migrant Health	6	\$782,528
Prion Surveillance	6	\$397,775
Rabies Surveillance & Laboratory Capacity	29	\$140,000
Parasitic Disease Surveillance	22	\$110,000
Enhanced Vaccine-Preventable Disease (VPD)	60	\$9,815,937
Legionnaires' Disease Prevention	36	\$3,940,000
Influenza Surveillance and Diagnostic Testing	57	\$9,400,000
Non-Influenza Respiratory Diseases: Diagnostics, Reporting, and Surveillance	40	\$1,000,000
Strengthening US Response to Resistant Gonorrhea (SURRG)	8	\$5,374,514
Gonococcal Isolate Surveillance Project (GISP)	21	\$600,000
Catalyzing Congenital Syphilis Prevention (CCSP)	4	\$1,589,624
Human Papillomavirus Surveillance Among Men	3	\$346,160
Infants with Congenital Exposures: Surveillance and Monitoring to Emerging Infectious Diseases and Other Health Threats	15	\$4,552,396

\*Data Modernization award made through COVID funding, not as part of the \$247M in Core ELC funding

<b>Total</b>		<b>\$197,040,089</b>
--------------	--	----------------------